ASPIRA PATHLAB & DIAGNOSTICS | LOTUS EYE CARE | ASPIRA PATHLAB & DIAGNOSTICS / LOTUS EYE CARE |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -13.6 | 35.9 | - | View Chart |
P/BV | x | 2.6 | 2.2 | 117.3% | View Chart |
Dividend Yield | % | 0.0 | 0.8 | - |
ASPIRA PATHLAB & DIAGNOSTICS LOTUS EYE CARE |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASPIRA PATHLAB & DIAGNOSTICS Mar-23 |
LOTUS EYE CARE Mar-23 |
ASPIRA PATHLAB & DIAGNOSTICS / LOTUS EYE CARE |
5-Yr Chart Click to enlarge
|
||
High | Rs | 75 | 97 | 77.4% | |
Low | Rs | 26 | 42 | 61.0% | |
Sales per share (Unadj.) | Rs | 14.0 | 22.6 | 62.1% | |
Earnings per share (Unadj.) | Rs | -0.1 | 2.0 | -4.4% | |
Cash flow per share (Unadj.) | Rs | 1.5 | 3.4 | 42.9% | |
Dividends per share (Unadj.) | Rs | 0 | 0.50 | 0.0% | |
Avg Dividend yield | % | 0 | 0.7 | 0.0% | |
Book value per share (Unadj.) | Rs | 12.4 | 27.7 | 44.8% | |
Shares outstanding (eoy) | m | 10.29 | 20.80 | 49.5% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 3.1 | 116.7% | |
Avg P/E ratio | x | -583.7 | 35.4 | -1,647.2% | |
P/CF ratio (eoy) | x | 34.6 | 20.5 | 169.0% | |
Price / Book Value ratio | x | 4.1 | 2.5 | 161.9% | |
Dividend payout | % | 0 | 25.5 | -0.0% | |
Avg Mkt Cap | Rs m | 518 | 1,445 | 35.9% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 56 | 85 | 65.6% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 145 | 470 | 30.7% | |
Other income | Rs m | 3 | 11 | 28.0% | |
Total revenues | Rs m | 148 | 482 | 30.7% | |
Gross profit | Rs m | 16 | 77 | 20.7% | |
Depreciation | Rs m | 16 | 30 | 53.2% | |
Interest | Rs m | 4 | 2 | 204.4% | |
Profit before tax | Rs m | -1 | 57 | -1.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 16 | 0.0% | |
Profit after tax | Rs m | -1 | 41 | -2.2% | |
Gross profit margin | % | 11.0 | 16.3 | 67.4% | |
Effective tax rate | % | 0 | 27.9 | -0.0% | |
Net profit margin | % | -0.6 | 8.7 | -7.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 59 | 147 | 39.8% | |
Current liabilities | Rs m | 16 | 52 | 30.5% | |
Net working cap to sales | % | 29.5 | 20.2 | 146.0% | |
Current ratio | x | 3.7 | 2.8 | 130.4% | |
Inventory Days | Days | 88 | 30 | 288.8% | |
Debtors Days | Days | 590 | 91 | 649.2% | |
Net fixed assets | Rs m | 115 | 481 | 23.9% | |
Share capital | Rs m | 103 | 208 | 49.5% | |
"Free" reserves | Rs m | 25 | 368 | 6.7% | |
Net worth | Rs m | 128 | 576 | 22.1% | |
Long term debt | Rs m | 10 | 0 | - | |
Total assets | Rs m | 173 | 628 | 27.6% | |
Interest coverage | x | 0.8 | 28.7 | 2.7% | |
Debt to equity ratio | x | 0.1 | 0 | - | |
Sales to assets ratio | x | 0.8 | 0.7 | 111.3% | |
Return on assets | % | 1.9 | 6.8 | 27.8% | |
Return on equity | % | -0.7 | 7.1 | -9.8% | |
Return on capital | % | 2.4 | 10.2 | 23.6% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 0 | 0 | - | |
Net fx | Rs m | 0 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 0 | 44 | -0.3% | |
From Investments | Rs m | 2 | -22 | -7.2% | |
From Financial Activity | Rs m | -9 | -17 | 54.8% | |
Net Cashflow | Rs m | -8 | 5 | -161.5% |
Indian Promoters | % | 18.7 | 22.6 | 82.8% | |
Foreign collaborators | % | 0.0 | 18.8 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 81.3 | 58.6 | 138.7% | |
Shareholders | 1,512 | 12,502 | 12.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASPIRA PATHLAB & DIAGNOSTICS With: APOLLO HOSPITALS DR. LAL PATHLABS NARAYANA HRUDAYALAYA METROPOLIS HEALTHCARE KIMS
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ASPIRA PATHLAB & DIAGNOSTICS | LOTUS EYE CARE | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 1.27% | 0.00% | 0.25% |
1-Month | -2.29% | 3.16% | 0.16% |
1-Year | -3.03% | -0.75% | 54.17% |
3-Year CAGR | 2.29% | 11.84% | 15.01% |
5-Year CAGR | -1.66% | 24.99% | 19.85% |
* Compound Annual Growth Rate
Here are more details on the ASPIRA PATHLAB & DIAGNOSTICS share price and the LOTUS EYE CARE share price.
Moving on to shareholding structures...
The promoters of ASPIRA PATHLAB & DIAGNOSTICS hold a 18.7% stake in the company. In case of LOTUS EYE CARE the stake stands at 41.4%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ASPIRA PATHLAB & DIAGNOSTICS and the shareholding pattern of LOTUS EYE CARE.
Finally, a word on dividends...
In the most recent financial year, ASPIRA PATHLAB & DIAGNOSTICS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
LOTUS EYE CARE paid Rs 0.5, and its dividend payout ratio stood at 25.5%.
You may visit here to review the dividend history of ASPIRA PATHLAB & DIAGNOSTICS , and the dividend history of LOTUS EYE CARE.
For a sector overview, read our pharmaceuticals sector report.
Asian stocks got off to a positive start on Monday ahead of the Federal Reserve's policy meeting later in the week.